Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.41 |
| ▸ | PTPRC | P08575 | 1/20 | 0.40 |
| ▸ | S100A4 | P26447 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29471963 | 1.00 | ALDH1A1 (0.56) | ALDH1A1HIF1ATDP1CYP3A4GAA | |
| SCHEMBL27492632 | 0.86 | ALDH1A1 (0.53) | ALDH1A1HIF1ATDP1CYP3A4GAA | |
| SCHEMBL260847 | 0.85 | ALDH1A1 (0.52) | ALDH1A1HIF1ATDP1CYP3A4GAA | |
| SCHEMBL29617011 | 0.85 | ALDH1A1 (0.52) | ALDH1A1HIF1ATDP1CYP3A4GAA | |
| SCHEMBL15076454 | 0.83 | ALDH1A1 (0.58) | ALDH1A1HIF1ATDP1GAATSHR | |
| SCHEMBL12955135 | 0.83 | ALDH1A1 (0.58) | ALDH1A1HIF1ATDP1CYP3A4GAA | |
| SCHEMBL29368452 | 0.82 | CYP1A2 (0.47) | ALDH1A1HIF1ATDP1CYP3A4TSHR | |
| SCHEMBL260864 | 0.82 | CYP1A2 (0.47) | ALDH1A1HIF1ATDP1CYP3A4TSHR | |
| SCHEMBL15679142 | 0.81 | ALDH1A1 (0.56) | ALDH1A1HIF1ATDP1GAATSHR | |
| SCHEMBL20560276 | 0.81 | ALDH1A1 (0.56) | ALDH1A1HIF1ATDP1GAATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 218 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137703-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECH LIMITED (GB) | 2026-05-21 | — | — | US | disclosed |
| EP-4612148-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | Cancer Research Technology Limited (GB) | 2025-09-10 | — | — | EP | disclosed |
| US-20240398776-A1 | INHIBITORS OF TGF-BETA R1 (ALK5) USEFUL TO TREAT CELL PROLIFERATION DISORDERS | NEXYS THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | US | disclosed |
| US-12102626-B2 | (Pyridin-2-yl)amine derivatives as TGF-BETA R1 (ALK5) inhibitors for the treatment of cancer | NEXYS THERAPEUTICS, INC. (US) | 2024-10-01 | — | — | US | disclosed |
| US-20240262795-A1 | PYRAZINE COMPOUNDS AS INHIBITORS OF FLT3 | BIOMEA FUSION, INC. | 2024-08-08 | — | — | US | disclosed |
| EP-4370506-A1 | PYRAZINE COMPOUNDS AS INHIBITORS OF FLT3 | Biomea Fusion, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| CN-114437062-B | Compound capable of being used as sodium channel regulator and application thereof | 成都海博为药业有限公司 | 2024-05-17 | — | — | CN | disclosed |
| WO-2024094963-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-05-10 | — | — | WO | disclosed |
| US-11945785-B2 | Pyrazine compounds as inhibitors of FLT3 | BIOMEA FUSION, INC. (US) | 2024-04-02 | — | — | US | disclosed |
| EP-3902796-B1 | (PYRIDIN-2-YL)AMINE DERIVATIVES AS TGF-BETA R1 (ALK5) INHIBITORS FOR THE TREATMENT OF CANCER | NEXYS THERAPEUTICS INC (US) | 2024-02-07 | — | — | EP | disclosed |
| US-5952362-A | INHIBITOR OF GLYCOGEN PHOSPHORYLASE ENZYMETIC ACTIVITY AND GLUCOSE ACITIVITY | SYNTEX (U.S.A) INC. (US) | 1999-09-14 | — | — | US | disclosed |
| EP-0889034-A1 | AMINOPYRIDINE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1999-01-07 | — | — | EP | disclosed |
| EP-0887346-A2 | Phenyl-and aminophenyl-alkylsulfonamide and urea derivatives, their preparation and their use as alpha1A/1L adrenoceptor agonists | F. HOFFMANN-LA ROCHE AG (CH) | 1998-12-30 | — | — | EP | disclosed |
| CN-1172473-A | Aniline derivatives having nitric oxide synthase inhibitory activity | CHUGAI PHARMACEUTICAL CO LTD (JP) | 1998-02-04 | — | — | CN | disclosed |
| EP-0798292-A1 | ANILINE DERIVATIVES HAVING NITROGEN MONOXIDE SYNTHASE INHIBITORY ACTIVITY | Chugai Seiyaku Kabushiki Kaisha (JP) | 1997-10-01 | — | — | EP | disclosed |
| US-4486355-A | INSECTICIDES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1984-12-04 | — | — | US | disclosed |
| US-4385070-A | CYCLOPROPANE DERIVATIVES AS INSECTICIDES | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1983-05-24 | — | — | US | disclosed |
| EP-0016513-B1 | ESTERS OF HALOGENATED SUBSTITUTED CYCLOPROPANOIC ACIDS, THEIR PREPARATION AND USE AS INSECTICIDES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1982-06-23 | — | — | EP | disclosed |
| EP-0032121-A2 | Substituted tetrafluorobenzyl alcohols and halides | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1981-07-15 | — | — | EP | disclosed |
| EP-0016513-A2 | Esters of halogenated substituted cyclopropanoic acids, their preparation and use as insecticides | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1980-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12102626-B2 | (Pyridin-2-yl)amine derivatives as TGF-BETA R1 (ALK5) inhibitors for the treatment of cancer | TGFBR1, TGFBR2, ACVR1 | ALDH1A1 419/4885HIF1A 1093/4885TDP1 1703/4885 |
| US-20240262795-A1 | PYRAZINE COMPOUNDS AS INHIBITORS OF FLT3 | FLT3, MCL1, CSF3R | ALDH1A1 2067/4885HIF1A 4038/4885TDP1 1169/4885 |
| US-20260137703-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | EGFR, KRAS, O60361 | ALDH1A1 999/4885HIF1A 3360/4885TDP1 1531/4885 |
| US-11945785-B2 | Pyrazine compounds as inhibitors of FLT3 | FLT3, MCL1, JAK2 | ALDH1A1 1320/4885HIF1A 3554/4885TDP1 1238/4885 |
| US-20240398776-A1 | INHIBITORS OF TGF-BETA R1 (ALK5) USEFUL TO TREAT CELL PROLIFERATION DISORDERS | ACVR1, TGFBR1, ACVRL1 | ALDH1A1 455/4885HIF1A 332/4885TDP1 2714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.